Genitourinary Cancers

The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

The addition of the off-the-shelf cancer immune primer ilixadencel to sunitinib trended toward a benefit in overall survival compared with sunitinib alone as a first-line treatment for patients with newly diagnosed metastatic renal cell carcinoma.

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.

David F. McDermott, MD, discusses the toxicities associated with immunotherapy combinations in renal cell carcinoma.

Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Ulka Vaishampayan, MD, discusses the shifting role of cytoreductive nephrectomy in renal cell carcinoma.

For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.